Silo Pharma (SILO) announced that the U.S. Patent and Trademark Office, USPTO, had issued a Notice of Allowance for U.S. Patent Application No. 17/954,858 that Silo licenses from Columbia University. The to-be-issued patent will further strengthen Silo’s IP protection for its lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder. The patent is expected to issue as U.S. Patent No. 12,329,726 on June 17, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SILO:
- Silo Pharma board approves purchase of bitcoin as treasury reserve
- Psychedelic: atai Life Sciences reports Phase 2a study data on BPL-003
- Silo Pharma, Resyca partner for intranasal drug-device study of SPC-15
- Silo Pharma Completes Public Offering, Raises $1.56 Million
- Silo Pharma prices 3.3M shares at 60c in public offering